During its Presidency of the Council of the European Union, the Government of the Netherlands has committed to improving affordable access to safe and effective medicines. But how can it create real and lasting change? Public health experts and government representatives debated these issues.
The event was coordinated by DNDi and other partners; AIDS Fonds, Médecins Sans Frontières (MSF), Health Action International (HAI), KNCV Tuberculosis Foundation (KNVC) and Universities Allied for Essential Medicines (UAEM).
Debate – Panel A
Diagnosing the problem of the current R&D model
A perspective on the lack of affordable access and innovation by James Love, Director of Knowledge Ecology International (KEI)
– Marietje Schaake, Member of European Parliament – ALDE/D66
Pitches of innovation
|1. WHO CEWG process as unique opportunity to implement alternative R&D models|
Sophie Bloemen, DNDi & Merle Schene, UAEM
|2. 3P Tuberculosis Proposal as example|
|3. Access through TRIPS flexibilities|
Jorrit Kabel, Aids Fonds
Debate – Panel B
How do we fix this?
New models of innovation – Principles and alternatives by David Hammerstein, Co-Director Commons Network
– James Love, Director of Knowledge Ecology International (KEI)
For more information: Health Action International Website